Current status: Answered by Humza Yousaf on 16 February 2022
To ask the Scottish Government what action it is taking to ensure an effective roll-out of the cystic fibrosis treatment, Kaftrio, to eligible children aged six to 11 years old.
Kaftrio ® has been available for the treatment of cystic fibrosis in patients aged 12 years and older since 1 September 2020. This follows a pricing agreement with the manufacturer. There is provision in the access policy and pricing agreement for expanding access to Kaftrio ® as licence extensions are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). The most recent extension in January 2022 allows for Kaftrio ® to be used in children aged 6 to 11 years.
This means that clinicians - working in cystic fibrosis treatment centres - can now prescribe Kaftrio ® for younger patients whom they consider will benefit from its use.